Literature DB >> 15818751

Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.

Jian-Gao Fan1, Lan Zhong, Li-Yan Tia, Zheng-Jie Xu, Min-Sheng Li, Guo-Liang Wang.   

Abstract

AIM: To evaluate the effects of ursodeoxycholic acid (UDCA) and/or low-calorie diet (LCD) on a rat model of nonalcoholic steatohepatitis (NASH).
METHODS: Fifty-five Sprague-Dawley rats were divided into five groups. The control group (n = 9) was fed with standard rat diet for 12 wk, NASH group (n = 10) was fed with high-fat diet consisted of normal diet, 10% lard oil and 2% cholesterol for 12 wk, UDCA group (n = 10) was fed with high-fat diet supplemented with UDCA at a dose of 25 mg/(kg.d) in drinking water for 12 wk, LCD group (n = 10) was fed with high-fat diet for 10 wk and then LCD for 2 wk, and UDCA+LCD group (n = 15) was fed with high-fat diet for 10 wk, followed by LCD+UDCA for 2 wk. At the end of the experiment, body weight, serum biochemical index, and hepatopathologic changes were examined.
RESULTS: Compared with the control group, rats in the NASH group had significantly increased body weight, liver weight, and serum lipid and aminotransferase levels. All rats in the NASH group developed steatohepatitis, as determined by their liver histology. Compared with the NASH group, there were no significant changes in body weight, liver weight, blood biochemical index, the degree of hepatic steatosis, and histological activity index (HAI) score in the UDCA group; however, body and liver weights were significantly decreased, and the degree of steatosis was markedly improved in rats of both the LCD group and the UDCA+LCD group, but significant improvement with regard to serum lipid variables and hepatic inflammatory changes were seen only in rats of the UDCA+LCD group, and not in the LCD group.
CONCLUSION: LCD might play a role in the treatment of obesity and hepatic steatosis in rats, but it exerts no significant effect on both serum lipid disorders and hepatic inflammatory changes. UDCA may enhance the therapeutic effects of LCD on steatohepatitis accompanied by obesity and hyperlipidemia. However, UDCA alone is not effective in the prevention of steatohepatitis induced by high-fat diet.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15818751      PMCID: PMC4305824          DOI: 10.3748/wjg.v11.i15.2346

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Non-alcoholic steatohepatitis: another disease of affluence.

Authors:  O James; C Day
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

2.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

3.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.

Authors:  Keith D Lindor; Kris V Kowdley; E Jenny Heathcote; M Edwyn Harrison; Roberta Jorgensen; Paul Angulo; James F Lymp; Lawrence Burgart; Patrick Colin
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

4.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 5.  Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.

Authors:  F Lirussi; L Okolicsanyi
Journal:  Ital J Gastroenterol       Date:  1992-01

6.  Effect of ursodeoxycholic acid on hepatic steatosis in rats.

Authors:  Abdullah Okan; Huseyin Astarcioglu; Ethem Tankurt; Ozgul Sagol; Emel Altekin; Ibrahim Astarcioglu; Omur Gonen
Journal:  Dig Dis Sci       Date:  2002-11       Impact factor: 3.199

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

Review 8.  Current best treatment for non-alcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  Expert Opin Pharmacother       Date:  2003-05       Impact factor: 3.889

9.  Ursodeoxycholate alleviates alcoholic fatty liver damage in rats.

Authors:  L Oliva; F Beaugé; D Choquart; A M Montet; M Guitaoui; J C Montet
Journal:  Alcohol Clin Exp Res       Date:  1998-10       Impact factor: 3.455

10.  Ursodeoxycholate protects against ethanol-induced liver mitochondrial injury.

Authors:  L Tabouy; A J Zamora; L Oliva; A M Montet; F Beaugé; J C Montet
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

View more
  8 in total

Review 1.  The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Monica D Chow; Yi-Horng Lee; Grace L Guo
Journal:  Mol Aspects Med       Date:  2017-05-05

2.  Protective effects of tiopronin against high fat diet-induced non-alcoholic steatohepatitis in rats.

Authors:  Jian-qing Wang; Yu-hong Zou; Cheng Huang; Chao Lu; Lei Zhang; Yong Jin; Xiong-wen Lü; Li-ping Liu; Jun Li
Journal:  Acta Pharmacol Sin       Date:  2012-04-30       Impact factor: 6.150

3.  [Steatohepatitis and cirrhosis: first manifestation 23 years after jejunoileal bypass surgery].

Authors:  Peter Piringer; Robert Buder; Fritz Firlinger; Christine Kapral; Christian Luft; Wolfgang Sega; Friedrich Wewalka; Kurt Lenz
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 4.  A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

Authors:  P Riley; J O'Donohue; M Crook
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

5.  Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic rats.

Authors:  N Niu; Y H Yu; Y Wang; L J Wang; Q Li; L M Guo
Journal:  Mol Biol Rep       Date:  2008-07-12       Impact factor: 2.316

6.  NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA.

Authors:  Yara Haddad; Diane Vallerand; Antoine Brault; Jean Spénard; Pierre S Haddad
Journal:  Int J Hepatol       Date:  2011-10-16

7.  Long term highly saturated fat diet does not induce NASH in Wistar rats.

Authors:  Caroline Romestaing; Marie-Astrid Piquet; Elodie Bedu; Vincent Rouleau; Marianne Dautresme; Isabelle Hourmand-Ollivier; Céline Filippi; Claude Duchamp; Brigitte Sibille
Journal:  Nutr Metab (Lond)       Date:  2007-02-21       Impact factor: 4.169

8.  The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).

Authors:  Ziwen Wang; Shanshan Li; Ruifeng Wang; Liansheng Guo; Dan Xu; Tieyuan Zhang; Yifan Xu; Wenlong Wang; Min Wang; Zhongwei Gan; Xiaobing Wang
Journal:  Mol Med       Date:  2020-06-05       Impact factor: 6.354

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.